ticlopidine has been researched along with Embolus in 35 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 9.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 9.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 9.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 5.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation." | 5.17 | Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. ( Buchbinder, M; Doshi, SK; Halperin, JL; Holmes, D; Huber, K; Neuzil, P; Reddy, VY; Sievert, H, 2013) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 5.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 5.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "The rapid and significant decline of MES in our stroke and TIA patients suggests the possible efficacy of dual antiplatelet therapy with aspirin and clopidogrel in patients with MES and symptomatic large-artery occlusive disease." | 3.73 | Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases. ( Chang, HM; Chen, CL; Esagunde, RU; Gan, HY; Lee, MP; Wong, KS; Wong, MC, 2006) |
| "Thrombosis is of greater overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders combined." | 2.41 | Antithrombotic agents: implications in dentistry. ( Henry, RG; Little, JW; McIntosh, BA; Miller, CS, 2002) |
| " Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database." | 1.42 | Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. ( Abe, J; Hara, H; Kinosada, Y; Miyamura, N; Nakamura, M; Nishibata, Y; Sekiya, Y; Suzuki, H; Suzuki, Y; Tsuchiya, T; Umetsu, R; Uranishi, H, 2015) |
| "Embolism is a dreaded complication of infective endocarditis (IE)." | 1.34 | Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. ( Anavekar, NS; Baddour, LM; Chandrasekaran, K; Haddad, C; Khandaker, MH; Mirzoyev, Z; Steckelberg, JM; Tleyjeh, IM; Wilson, WR, 2007) |
| "Although saddle embolism is a relatively rare event, orthopaedic surgeons should be aware of this condition." | 1.33 | Saddle embolism after corrective femoral osteotomy: a case report. ( Hoshino, Y; Kariya, Y; Konishi, H; Noguchi, K; Ohashi, Y; Sekiya, H, 2006) |
| "The ER of the ball thrombus type group, especially the MB group, was very high in spite of therapy with anti-coagulants and/or anti-platelet agents, and such patients should be treated by early surgical intervention." | 1.32 | Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus. ( Abe, Y; Asakura, T; Gotou, J; Ishikawa, S; Iwai, M; Maehara, K; Maruyama, Y; Muroi, S; Nagata, K; Ono, M; Saitoh, F; Sakabe, A; Sakamoto, N; Sando, M; Satoh, M; Suzuki, S; Watanabe, Y, 2003) |
| "A plaque embolism was excluded clinically and in the contrast-medium intensified MRT 5 days after the intervention in 79/81 (97." | 1.32 | [Outpatient primary stent-angioplasty in symptomatic internal carotid artery stenoses]. ( Andresen, R; Brinckmann, W; Roth, M, 2003) |
| "or more) also suppressed the thrombus formation by single administration." | 1.29 | Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. ( Doi, H; Kaburaki, M; Murata, S; Narita, H; Yasoshima, A, 1995) |
| "Ticlopidine treatment was associated with increased platelet numbers in all 5 dogs during the heartworm-negative stage and in 4 of 5 dogs during the heartworm implantation and heartworm embolization stages." | 1.28 | Effects of treatment with ticlopidine in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. ( Boudreaux, MK; Dillon, AR; Ravis, WR; Sartin, EA; Spano, JS, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.86) | 18.7374 |
| 1990's | 3 (8.57) | 18.2507 |
| 2000's | 20 (57.14) | 29.6817 |
| 2010's | 11 (31.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graham, BR | 1 |
| Menon, BK | 1 |
| Mahaffey, KW | 1 |
| Stevens, SR | 1 |
| White, HD | 1 |
| Nessel, CC | 1 |
| Goodman, SG | 1 |
| Piccini, JP | 1 |
| Patel, MR | 1 |
| Becker, RC | 1 |
| Halperin, JL | 2 |
| Hacke, W | 2 |
| Singer, DE | 1 |
| Hankey, GJ | 1 |
| Califf, RM | 1 |
| Fox, KA | 1 |
| Breithardt, G | 1 |
| Amarenco, P | 1 |
| Davis, S | 1 |
| Jones, EF | 1 |
| Cohen, AA | 1 |
| Heiss, WD | 1 |
| Kaste, M | 1 |
| Laouénan, C | 1 |
| Young, D | 1 |
| Macleod, M | 1 |
| Donnan, GA | 1 |
| Suzuki, Y | 1 |
| Suzuki, H | 1 |
| Umetsu, R | 1 |
| Uranishi, H | 1 |
| Abe, J | 1 |
| Nishibata, Y | 1 |
| Sekiya, Y | 1 |
| Miyamura, N | 1 |
| Hara, H | 1 |
| Tsuchiya, T | 1 |
| Kinosada, Y | 1 |
| Nakamura, M | 1 |
| Blann, AD | 1 |
| Skjøth, F | 1 |
| Rasmussen, LH | 1 |
| Larsen, TB | 1 |
| Lip, GY | 1 |
| Sasaki, K | 1 |
| Ueno, T | 1 |
| Windecker, S | 1 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| Mehran, R | 1 |
| Valgimigli, M | 1 |
| Vranckx, P | 1 |
| Welsh, RC | 1 |
| Baber, U | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 1 |
| Connolly, SJ | 1 |
| Pogue, J | 1 |
| Hart, RG | 1 |
| Hohnloser, SH | 1 |
| Pfeffer, M | 1 |
| Chrolavicius, S | 1 |
| Yusuf, S | 1 |
| Yamasaki, H | 1 |
| Matsubara, S | 1 |
| Sasaki, I | 1 |
| Nagahiro, S | 1 |
| Feldman, DN | 1 |
| Wong, SC | 1 |
| Bergman, G | 1 |
| Minutello, RM | 1 |
| Chua, D | 1 |
| Legal, M | 1 |
| Shalansky, SJ | 1 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Schwalm, JD | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Eikelboom, JW | 1 |
| Natarajan, MK | 1 |
| Laufs, U | 1 |
| Hoppe, UC | 1 |
| Rosenkranz, S | 1 |
| Kirchhof, P | 1 |
| Böhm, M | 1 |
| Diener, HC | 1 |
| Endres, M | 1 |
| Grond, M | 1 |
| Meinertz, T | 1 |
| Ringelstein, EB | 2 |
| Röther, J | 1 |
| Dichgans, M | 1 |
| Naidu, SS | 1 |
| Turco, MA | 1 |
| Mauri, L | 1 |
| Coolong, A | 1 |
| Popma, JJ | 1 |
| Kereiakes, DJ | 1 |
| Reddy, VY | 1 |
| Doshi, SK | 1 |
| Sievert, H | 1 |
| Buchbinder, M | 1 |
| Neuzil, P | 1 |
| Huber, K | 1 |
| Holmes, D | 1 |
| Abe, Y | 1 |
| Asakura, T | 1 |
| Sakamoto, N | 1 |
| Ishikawa, S | 1 |
| Muroi, S | 1 |
| Saitoh, F | 1 |
| Satoh, M | 1 |
| Suzuki, S | 1 |
| Ono, M | 1 |
| Sakabe, A | 1 |
| Iwai, M | 1 |
| Sando, M | 1 |
| Gotou, J | 1 |
| Watanabe, Y | 1 |
| Nagata, K | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Andresen, R | 1 |
| Roth, M | 1 |
| Brinckmann, W | 1 |
| Massie, BM | 1 |
| Krol, WF | 1 |
| Ammon, SE | 1 |
| Armstrong, PW | 1 |
| Cleland, JG | 1 |
| Collins, JF | 1 |
| Ezekowitz, M | 1 |
| Jafri, SM | 1 |
| O'Connor, CM | 1 |
| Packer, M | 1 |
| Schulman, KA | 1 |
| Teo, K | 1 |
| Warren, S | 1 |
| Markus, HS | 1 |
| Droste, DW | 1 |
| Kaps, M | 1 |
| Larrue, V | 1 |
| Lees, KR | 1 |
| Siebler, M | 1 |
| Patti, G | 1 |
| Pasceri, V | 1 |
| Nusca, A | 1 |
| Di Sciascio, G | 1 |
| Imray, CH | 1 |
| Higman, DJ | 1 |
| Marshall, C | 1 |
| Cohen, SN | 1 |
| Esagunde, RU | 1 |
| Wong, KS | 1 |
| Lee, MP | 1 |
| Gan, HY | 1 |
| Wong, MC | 1 |
| Chang, HM | 1 |
| Chen, CL | 1 |
| Spengos, K | 1 |
| Tsivgoulis, G | 1 |
| Toulas, P | 1 |
| Sameli, S | 1 |
| Vassilopoulou, S | 1 |
| Zakopoulos, N | 1 |
| Sfagos, K | 1 |
| Heiss, JM | 1 |
| Sekiya, H | 1 |
| Noguchi, K | 1 |
| Ohashi, Y | 1 |
| Kariya, Y | 1 |
| Hoshino, Y | 1 |
| Konishi, H | 1 |
| Anavekar, NS | 2 |
| Tleyjeh, IM | 1 |
| Mirzoyev, Z | 1 |
| Steckelberg, JM | 1 |
| Haddad, C | 1 |
| Khandaker, MH | 1 |
| Wilson, WR | 1 |
| Chandrasekaran, K | 1 |
| Baddour, LM | 1 |
| Henry, M | 1 |
| Henry, I | 1 |
| Polydorou, A | 2 |
| Hugel, M | 1 |
| Narita, H | 1 |
| Kaburaki, M | 1 |
| Doi, H | 1 |
| Yasoshima, A | 1 |
| Murata, S | 1 |
| Bechich, S | 1 |
| Arboix, A | 1 |
| Kuroda, Y | 1 |
| Hara, K | 1 |
| Nakajima, H | 1 |
| Ikari, Y | 1 |
| Little, JW | 1 |
| Miller, CS | 1 |
| Henry, RG | 1 |
| McIntosh, BA | 1 |
| Boudreaux, MK | 1 |
| Dillon, AR | 1 |
| Sartin, EA | 1 |
| Ravis, WR | 1 |
| Spano, JS | 1 |
| Nuttall, A | 1 |
| Smith, HJ | 1 |
| Loveday, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248] | Phase 3 | 350 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [NCT02937025] | Phase 1/Phase 2 | 154 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)[NCT00129545] | Phase 2/Phase 3 | 800 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212] | 2,931 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-10-13 | Completed | ||
| Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794] | 300 participants (Actual) | Observational [Patient Registry] | 2018-03-14 | Completed | |||
| Feasibility and Prognostic Role of Percutaneous Left Atrial Appendage Closure in Patients With Heart Failure and Atrial Fibrillation at High Risk for Cerebrovascular Events[NCT04472871] | 300 participants (Anticipated) | Observational | 2020-07-20 | Not yet recruiting | |||
| CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683] | Phase 3 | 1,587 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups[NCT01645306] | Phase 2 | 158 participants (Actual) | Interventional | 2013-03-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
A Bayesian model allowed for sequential evaluation of the primary endpoints, event rates reported per 100 patient-years (calculated as 100*N events/Total patient-years) (NCT00129545)
Timeframe: 5 years
| Intervention | events per 100 pt yrs (Number) |
|---|---|
| Implantable Device | 2.2 |
| Warfarin Control | 3.7 |
Implant procedure success is defined as the delivery and release of a WATCHMAN Device into the LAA. (NCT00129545)
Timeframe: Initial implant procedure
| Intervention | percentage of implant attempts (Number) |
|---|---|
| WATCHMAN | 90.9 |
Serious bleeding events evaluated by the Clinical Events Committee included pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion, and any bleeding related to the device or procedure that necessitates an operation. (NCT00129545)
Timeframe: 5 years
| Intervention | Events per 100 pt-yrs (Number) |
|---|---|
| Implantable Device | 3.5 |
| Warfarin Control | 3.2 |
"Anti-drug antibodies were measured at baseline and 3 month after IMP application.~Number of patients with positive anti-drug antibodies compared to baseline are counted." (NCT01645306)
Timeframe: 3 month (+/- 1 month) after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| 40 mg Revacept | 0 |
| 120 mg Revacept | 0 |
patients with any stroke & TIA, myocardial infarction & percutaneous coronary intervention (PCI), death or bleeding within one year (365 days) after IMP application. (NCT01645306)
Timeframe: 365 days after IMP application
| Intervention | Number of Events (Number) |
|---|---|
| Placebo | 19 |
| 40 mg Revacept | 15 |
| 120 mg Revacept | 10 |
patients with major bleedings occuring within 90 days after IMP application (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline). (NCT01645306)
Timeframe: 1 day post intervention
| Intervention | Number of new lesions (Mean) |
|---|---|
| Placebo | 1.2 |
| 40 mg Revacept | 1.0 |
| 120 mg Revacept | 0.6 |
patients with any stroke or TIA occuring within 90 days after IMP application. (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
All adverse events were assessed during complete study period (~ 1 year after IMP application). (NCT01645306)
Timeframe: ~ 365 days after IMP application (whole study period)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| patients with adverse events | patients with drug related AEs | patients with serious AEs | patients with drug related serious AEs | patients with AE with fatal outcome events | |
| 120 mg Revacept | 32 | 2 | 15 | 0 | 1 |
| 40 mg Revacept | 41 | 10 | 17 | 4 | 0 |
| Placebo | 35 | 4 | 17 | 1 | 0 |
3 reviews available for ticlopidine and Embolus
| Article | Year |
|---|---|
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug | 2015 |
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholestere | 2005 |
Antithrombotic agents: implications in dentistry.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embol | 2002 |
9 trials available for ticlopidine and Embolus
23 other studies available for ticlopidine and Embolus
| Article | Year |
|---|---|
Clopidogrel Load Reduces Emboli in Carotid Artery Stenosis With Free-Floating Thrombus.
Topics: Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Embolism; Humans; Magnetic Resonance Imagin | 2017 |
Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Comb | 2015 |
[CHARISMA study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Embolism; Female; Humans; Male; Middle Aged; Plaque, | 2016 |
Retinal artery embolization during carotid angioplasty and carotid artery stenting: case report.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Antipyrine; Aspirin; Carotid Artery, External; Carotid S | 2009 |
Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; | 2010 |
Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus.
Topics: Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combination; Echocardiograp | 2003 |
[Outpatient primary stent-angioplasty in symptomatic internal carotid artery stenoses].
Topics: Aged; Angiography; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid Artery, Internal; Carotid | 2003 |
Letter regarding article by Markus et al, "Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic cardiac stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Platelet Aggreg | 2005 |
Letter regarding article by Markus et al, "Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic cardiac stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Platelet Aggreg | 2005 |
Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases.
Topics: Aged; Aspirin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Embolism; F | 2006 |
Spinal cord stroke in a ballet dancer.
Topics: Accidents, Occupational; Adult; Clopidogrel; Dancing; Embolism; Female; Fibrocartilage; Humans; Inte | 2006 |
[Emergency measures in acute arterial occlusion. Why there are still colleagues who do it incorrectly?].
Topics: Acute Disease; Angiography; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Embolism; Emergencies | 2006 |
Saddle embolism after corrective femoral osteotomy: a case report.
Topics: Arterial Occlusive Diseases; Atrial Fibrillation; Echocardiography, Transesophageal; Embolectomy; Em | 2006 |
Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Administration Sche | 2007 |
Endovascular treatment of a renal artery stenosis: techniques, indications, results. Role of embolic protection devices (part 2).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Catheterization; Clopidogrel; Embolism; Fibrinolyt | 2007 |
Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats.
Topics: Administration, Oral; Animals; Antithrombins; Aspirin; Diltiazem; Dose-Response Relationship, Drug; | 1995 |
[Significant regression of neurological hemispheric deficit].
Topics: Acute Disease; Aged; Cerebral Infarction; Embolism; Female; Heart; Humans; Platelet Aggregation Inhi | 1997 |
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang | 2001 |
Effects of treatment with ticlopidine in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Collagen; Dirofilariasis; Dog Diseases; Dogs; Embol | 1991 |
A clinically relevant model of heart failure: effects of ticlopidine.
Topics: Animals; Blood Pressure; Coronary Circulation; Disease Models, Animal; Embolism; Female; Heart Failu | 1985 |